Kevin Krause is Vice President of Clinical Sciences and Development at AN2 Therapeutics, a company he joined in November 2019. Here, he focuses on the development of treatments for infectious diseases with a high unmet need.
Before joining AN2 Therapeutics, Kevin was part of the senior leadership team at Achaogen. During his time there, Kevin led plazomicin out-licensing efforts for key regions. He also played an instrumental role in the phase 3 development programme, regulatory defense and launch of this drug. He was a co-inventor of the C-scape programme.
Kevin has more than 21 years of experience in the biotechnology and pharmaceutical industries spanning R&D, corporate development, competitive intelligence, commercial strategy and operations within the antibacterial space. He has been a key contributor for three US investigational new drugs, five new drug applications and marketing authorization applications, five US FDA Anti-infective Drug Advisory Committee meetings and numerous product launches in both the US and Europe.
From 2010-14, Kevin was a member of the Clinical Microbiology team at Cerexa, Inc. (a subsidiary of Actavis which is now Allergan) where, amongst other activities, he oversaw all microbiology activities related to clinical development for ceftazidime-avibactam (approved as AVYCAZ®).